Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

Solid Tumor Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of HLX22 Monoclonal Antibody Injection (HER2 Monoclonal Antibody) in Patients With Advanced Solid Tumours Overexpressing HER2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03916094
• Other study ID #: HLX22-001
• Status: Completed
• Phase: Phase 1
• Start date: July 31, 2019
• Est. completion date: December 27, 2021

Study information

• Verified date: April 2022
• Source: Shanghai Henlius Biotech
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX22 in patients with advanced solid tumors overexpressing HER2 after failure of standard of care.

Description:

This study is an open-label and dose escalation study aimed at exploring the safety and MTD of HLX22.

three dose levels are designed for HLX22 in this study: 3, 10, and 25 mg/kg/3 weeks. The 3 mg/kg/3 weeks will serve as the starting dose. The study will use a 3+3 design to assign doses to the patients, and thereby determine the MTD of HLX22.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: December 27, 2021
• Est. primary completion date: January 4, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Patients with child-bearing potential must agree to and be able to use effective contraceptive measures.

At least 28 days from prior major surgery, prior cytotoxic chemotherapy, prior hormonal therapy (except for androgen-deprivation therapy in patients with prostate cancer), prior therapy with investigational products (or medical device) or local radiotherapy, at least 42 days from prior chemotherapy with nitrosoureas or mitomycin C, and at least 42 days from prior immunotherapy before the first dose of HLX22.

At least one bi-dimensionally measurable lesion to be used as the basis for evaluation.

ECOG performance status of = 1 at study entry. Patients with histologically-proven HER2-positive advanced or metastatic solid tumours who are either non-responsive or intolerant to standard therapies.

HER2-positive tumours that are confirmed by immunohistochemistry (IHC) and:

1. HER2 mutation of at least 3+ (+++) or

2. HER2 mutation of at least 2+ (++) and fluorescence in situ hybridization (FISH) test positive.

Adequate haematologic functions Adequate hepatic functions Adequate renal functions Adequate cardiac functions For patients with hepatocellular carcinoma, Child-Pugh score has to be A. Able to receive treatment and examinations as required by the study protocol. Life expectancy > 3 months. Exclusion Criteria Patients with history of alcohol or drug abuse, or positive for alcohol breath test before dosing.

Patients who still have = Grade 2 toxicities from prior therapies (except for Grade 2 alopecia).

Concurrent unstable or uncontrolled medical conditions with either of the following:

• Active systemic infections requiring intravenous antibiotic;

• Poorly controlled hypertension, or poor compliance with anti-hypertensive agents;

• Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (New York Heart Association [NYHA] Grade III or IV) or acute myocardial infarction within 6 months;

• Uncontrolled diabetes mellitus or poor compliance with hypoglycemics;

• NCI CTCAE Grade = 2 hypercalcemia;

• Presence of chronically unhealed wound or ulcers;

• Other chronic diseases which, in the opinion of the Investigator, may compromise the safety of the patient or the integrity of the study.

Patients with history of interstitial lung disease. Patients with newly diagnosed or symptomatic brain metastases Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix (patients with a previous malignancy but without evidence of disease for = 3 years can participate).

Patients have received a cumulative dose of doxorubicin (or equivalent) of = 360 mg/m2.

Patients have participated in another clinical study within 4 weeks (in the case of a clinical study of a monoclonal antibody drug, 3 months or 5 half-lives, whichever is longer) prior to the enrolment, or patients have intended to participate in another clinical study during the period of the study.

Female patients in pregnancy (confirmed by ß-HCG test) or breastfeeding. Known history of human immunodeficiency virus (HIV) infection. Patients with active hepatitis B (positive for hepatitis B core antibody [HBcAb], or hepatitis B surface antigen [HBsAg], along with hepatitis B virus [HBV] DNA titre > the limit of normal defined by the study site), or hepatitis C (positive for hepatitis C antibody).

-

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• HLX22
Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody

Locations

Country	Name	City	State
China	First Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Henlius Biotech

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2	The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%).	from day1 to day 42(cycle 1 and cycle2 ,each cycle is 21days)
Secondary	the pharmacokinetic characteristics of HLX22 at different doses in patients.	Area under the plasma concentration versus time curve (AUC) for single dose and multiple doses	cycle1 to cycle 8 ,and 28-day follow-up visit after the last infusion (if possible),(each cycle is 21 days).
Secondary	the pharmacodynamic characteristics of HLX22 at different doses in patients	the concentration of soluble HER1 and HER2 in serum	cycle 1 to cycle 6 (each cycle is 21 days)
Secondary	the immunogenicity of HLX22 in humans	anti-HLX22 antibodies in serum	cycle 1 to cycle 6 (each cycle is 21 days)